FDA Determines Regulatory Review Period for SHINGRIX Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of SHINGRIX, a human biological product, following a submission to the U.S. Patent and Trademark Office (USPTO).